MILESTONE SCIENTIFIC INC

Company Overview

Milestone Scientific (ticker MLSS) is a small, IP‑centric Healthcare company in the Medical Instruments & Supplies industry that commercializes computer‑controlled drug‑delivery systems built on its proprietary DPS (Dynamic Pressure Sensing) technology. Its core products are the dental Wand/STA disposable handpieces and controllers and the CompuFlo medical platform (notably the CompuFlo Epidural System), sold via U.S. e‑commerce and international distributors across 41+ countries. Operations are lean (≈17 employees), manufacturing is outsourced, and the company relies on a large patent estate (~317 patents), FDA 510(k) clearances, a CPT code and regional reimbursement assignments to drive medical adoption. Financially it is microcap‑sized (2024 product sales ≈ $8.6M), loss‑making but improving operating dynamics in part due to nonrecurring items, and it continues to face going‑concern and financing risks while prioritizing commercialization of CompuFlo.

Executive Compensation Practices

Given Milestone’s small revenue base and constrained cash position, executives in this Healthcare / Medical Instruments & Supplies context are likely to receive modest cash salaries supplemented by equity‑based pay (stock options, restricted shares) and milestone or retention awards to conserve cash. Company‑specific compensation metrics will logically emphasize commercialization milestones—FDA clearances/label expansions, CPT/reimbursement achievements, distribution partnerships, recurring disposable handpiece revenue and gross margin improvement (dental gross margin ~74% in 2024)—rather than GAAP net income that can be skewed by one‑time NOL sales. R&D and SG&A discipline, conversion of CompuFlo medical milestones into recurring revenue, and successful financing events are all natural performance levers for bonuses or long‑term awards. Board compensation design should also account for dilution risk from future financings and option pools, and may preferentially use time‑vesting and milestone‑vesting equity to align management with commercialization outcomes.

Insider Trading Considerations

With a small public float, low trading liquidity and material sensitivity to regulatory/reimbursement milestones, insider transactions at Milestone can carry outsized informational and market impact—executive buys may signal confidence in commercial rollouts while sales can reflect liquidity needs or hedging against dilution. Key events that create material nonpublic information for trading windows include FDA clearances/label expansions, CPT/Medicare pricing outcomes, major distribution agreements, and capital raises; insiders must observe Section 16 reporting, blackout/pre‑clearance policies and 10b5‑1 plan disclosures where applicable. The company’s recent reliance on one‑time proceeds (sale of NOLs) and related‑party financing (April 2025 note) raises the need to scrutinize affiliated transactions and disclosures for potential conflicts of interest. Finally, expect insider selling tied to option exercises, personal liquidity needs or impending dilution from financings; conversely, insider purchases during financing‑sensitive periods can be a higher‑conviction positive signal for traders and researchers.